Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00381875 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy, Incomplete Freund's Adjuvant, and GM-CSF in Treating Patients With HIV
A Phase 1 study, sponsored by National Institutes of Health Clinical Center (CC).
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00381875 is a Phase 1 study that has completed, run by National Institutes of Health Clinical Center (CC). The registered enrollment target is 40 participants.
The verdict
NCT00381875, a Phase 1 study, has completed, sponsored by National Institutes of Health Clinical Center (CC).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from peptides may help the body build an effective immune response. Incomplete Freund's adjuvant may stimulate the immune system in different ways and may help the vaccine work better. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or peripheral blood. Giving vaccine therapy together with incomplete Freund's adjuvant and GM-CSF may be an effective treatment for patients with HIV. PURPOSE: This clinical trial is studying how well giving vaccine therapy together with incomplete Freund's adjuvant and GM-CSF works in treating patients with HIV.
Interventions
- BIOLOGICAL sargramostim
- OTHER immunoenzyme technique
- BIOLOGICAL incomplete Freund's adjuvant
- BIOLOGICAL E1M184V peptide vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2006-07 |
| Est. Completion | 2011-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00381875
The ClinicalTrials.gov registry entry for NCT00381875 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institutes of Health Clinical Center (CC), which has 338 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which sargramostim is the first listed.
NCT00381875 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00381875 about?
NCT00381875 is a clinical study titled "Vaccine Therapy, Incomplete Freund's Adjuvant, and GM-CSF in Treating Patients With HIV". RATIONALE: Vaccines made from peptides may help the body build an effective immune response. Incomplete Freund's adjuvant may stimulate the immune system in different ways and may help the vaccine work better. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found ...
What is the current status of trial NCT00381875?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2006-07. Estimated completion is 2011-02.
What interventions are being tested in trial NCT00381875?
The interventions under investigation include: sargramostim (BIOLOGICAL), immunoenzyme technique (OTHER), incomplete Freund's adjuvant (BIOLOGICAL), E1M184V peptide vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00381875?
This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.